Inactive Instrument

CinCor Pharma, Inc.

Equities

CINC

US17240Y1091

Biotechnology & Medical Research

CinCor Pharma to Present at the 32nd Annual Oppenheimer Healthcare Conference

March 03, 2022 at 09:16 am EST

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that its management team will present at the 32^nd Annual Oppenheimer Healthcare Conference taking place March 15-17, 2022.


Event:	32^nd Annual Oppenheimer Healthcare Conference
Presentation:	Wednesday, March 16, 2022 at 10 am EST

Management will also meet with investors during the event. Investors interested in meeting with the CinCor management team during the conference should contact their Oppenheimer & Co. representative.

About CinCor

CinCor is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, for the treatment of hypertension and other cardio-renal diseases.

Contacts:
Terry Coelho
CinCor Pharma, Inc.
EVP, CFO and CBDO

Investors:
Bob Yedid
LifeSci Advisors
ir@CinCor.com

Latest news about CinCor Pharma, Inc.

AstraZeneca Completes $1.8 Billion Acquisition of CinCor Pharma to Boost Cardiorenal Portfolio	23-02-24	MT
AstraZeneca closes CinCor buy; Enhertu wins Chinese approval	23-02-24	AN
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from NASDAQ Composite Index	23-02-24	CI
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from S&P Global BMI Index	23-02-24	CI
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from S&P TMI Index	23-02-24	CI
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from NASDAQ Biotechnology Index	23-02-23	CI
Astrazeneca Finance And Holdings Inc. completed the acquisition of CinCor Pharma, Inc. from a group of shareholders.	23-02-22	CI
CinCor Pharma, Inc. Announces Completion of End-of-Phase 2 Meeting with U.S. Food and Drug Administration on Anticipated Phase 3 Program for Baxdrostat in Hypertension	23-02-21	CI
AstraZeneca Initiates Tender Offer For $2 Billion CinCor Takeover	23-01-23	MT
ADRs End Higher; AstraZeneca, Barclays Trade Actively	23-01-23	DJ
Biotech IPO Window to Reopen in 2023 Following Muted Activity in 2022, Oppenheimer Says	23-01-23	MT
AstraZeneca Unit Starts Tender Offer to Purchase CinCor Pharma	23-01-23	MT
North American Morning Briefing : Big Day For Bank -2-	23-01-13	DJ
Barclays Downgrades CinCor Pharma to Equal-Weight Rating From Overweight, Adjusts Price Target to $31 From $22	23-01-12	MT
Morgan Stanley Adjusts Price Target on CinCor Pharma to $30 From $22, Maintains Equal-Weight Rating	23-01-10	MT
MarketScreener's World Press Review: January 10	23-01-10
Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup	23-01-09	DJ
Sector Update: Health Care Stocks Largely Struggle Monday	23-01-09	MT
Top Midday Gainers	23-01-09	MT
Sector Update: Health Care Stocks Struggling to Begin New Week	23-01-09	MT
FTSE 100 Closed Up Boosted by China Reopening	23-01-09	DJ
European Markets Advance as Germany Eases Recession Fears	23-01-09	MT
Global markets live: Alibaba, Qiagen, Macy's, Oracle, Chevron...	23-01-09
The return of optimism	23-01-09
Sterling to Rally if UK GDP Data Beat Forecasts	23-01-09	DJ

Chart CinCor Pharma, Inc.

Duration

Period

More charts

Company Profile

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the target of providing an improved treatment for patients suffering from hypertension, or high blood pressure. In addition to hypertension, the Company is developing CIN-107 for the treatment of primary aldosteronism (PA) and exploring its utility in ameliorating complications of chronic kidney disease (CKD). It also exploring its utility in ameliorating complications of CKD. It is conducting a Phase II clinical trial, which it refers to as its BrigHtn trial.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	105B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.53%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.09%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	14.09B
SAREPTA THERAPEUTICS, INC.	+28.85%	10.99B

Bio Therapeutic Drugs